Jaypirca (pirtobrutinib) — United Healthcare

Initial criteria

• Diagnosis of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma which has been previously treated

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Jaypirca therapy

Approval duration

12 months